Literature DB >> 8351363

Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion.

K Kandarpa1, P S Chopra, J E Aruny, J F Polak, M C Donaldson, A D Whittemore, J A Mannick, S Z Goldhaber, M F Meyerovitz.   

Abstract

A prospective randomized controlled trial compared forced infusion (FI) of urokinase (UK) with conventional slow continuous infusion (CI) in 25 patients with 25 acutely ischemic lower limbs. Demographics, ischemia categories, and infusion rates and doses were similar for both groups. A preliminary single-pass bolus of UK was injected into the thrombus in all patients with a pulsed-spray technique, and heparin was administered. UK was then infused with a CI pump (n = 13) or a prototype pulsed-spray pump (n = 12). The primary end point was patency, defined as at least 95% thrombolysis by volume, with brisk antegrade flow occurring within 4 hours. Eleven of the 12 patients (92%) who underwent FI and nine of the 13 (70%) who underwent CI had patency within 4 hours. However, 10 patients who underwent FI and nine who underwent CI had residual thrombi prolonging infusion. No significant differences between the two groups were apparent in speed of lysis, initial success rates, complication rates, or 30-day clinical outcome. Lytic therapy, however, was completed within 24 hours in 18 of 23 (78%) successfully treated patients (P = .01).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8351363     DOI: 10.1148/radiology.188.3.8351363

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Catheter-directed thrombolysis for acute limb ischemia.

Authors:  Harry L Morrison
Journal:  Semin Intervent Radiol       Date:  2006-09       Impact factor: 1.513

Review 2.  Infusion techniques for peripheral arterial thrombolysis.

Authors:  Cathryn Broderick; Jai V Patel
Journal:  Cochrane Database Syst Rev       Date:  2021-11-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.